J. Marshall

A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C)

Charles S. Fuchs, J. Marshall, Edith P. Mitchell et al. · Journal of Clinical Oncology · 2006 · 54 citations

Medicine, Oncology, Pharmacology +12

G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study

J. Shapiro, J. Marshall, Petr Karásek et al. · Journal of Clinical Oncology · 2005 · 45 citations

Medicine, Oncology, Pharmacology +17

A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors

Nicole Lewis, J. Marshall, A. Amelsberg et al. · Journal of Clinical Oncology · 2006 · 23 citations

Medicine, Oncology, Pharmacology +7

Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.

Michael A. Morse, Donna Niedzwiecki, J. Marshall et al. · Journal of Clinical Oncology · 2011 · 12 citations

Life Sciences, Immunology, Oncology +17

Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients >65 years compared with those ≤65: The BICC-C study

José Barrueco, J. Marshall, E. Mitchell et al. · Journal of Clinical Oncology · 2007 · 10 citations

Medicine, Pharmacology, Pharmacotherapy +10